Summit Presents Updated Ivonescimab Data at ELCC 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy SMMT?
Source: Newsfilter
- Clinical Data Update: Summit Therapeutics will present updated data on ivonescimab at the 2026 European Lung Cancer Congress, covering intracranial anti-tumor activity from the global HARMONi Phase III study, which is expected to attract industry attention and enhance the company's reputation in cancer immunotherapy.
- Improved Intracranial Survival: In the HARMONi study, patients receiving ivonescimab plus chemotherapy showed an intracranial progression-free survival (PFS) of 10.1 months compared to 6.5 months for chemotherapy alone, indicating the potential advantage of this therapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients.
- Quality of Life Assessment: The second poster will showcase health-related quality of life data comparing ivonescimab with placebo plus chemotherapy, emphasizing the drug's potential to improve patient quality of life, which may enhance market recognition.
- Multiple Ongoing Trials: Ivonescimab is currently involved in over 15 Phase III clinical trials globally, covering various cancer types, indicating the company's extensive positioning in cancer treatment and future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMMT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMMT
Wall Street analysts forecast SMMT stock price to rise
12 Analyst Rating
8 Buy
3 Hold
1 Sell
Moderate Buy
Current: 16.980
Low
18.00
Averages
42.49
High
131.90
Current: 16.980
Low
18.00
Averages
42.49
High
131.90
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Citi Identifies Stocks with Upside Amid U.S.-Iran Conflict
- Market Turmoil Impact: The ongoing U.S.-Iran conflict has caused concern among investors, leading to a nearly 8% drop in the S&P 500 in March, marking its worst monthly performance since 2022.
- Citi Analyst Strategy: Citi analyst Richard Schlatter sought stocks that could sidestep recent volatility by overlaying crowding composites tracked by Citi, identifying stocks with positive catalysts that are not relatively crowded, aiming for a favorable reaction to fundamental tailwinds.
- Delta Air Lines Outlook: Delta Air Lines' stock has only dropped 3.8% this month, despite a nearly 9% decline in 2026, with Wall Street expecting a rebound; the average analyst price target from LSEG suggests a potential 25% gain over the next year.
- Summit Therapeutics Performance: Summit Therapeutics' stock has risen 2.4% since the war began, with a long crowding composite of just 18.1%, and analysts are generally bullish, as 13 out of 18 covering analysts rate it a buy or strong buy.
See More
Summit Presents Updated Ivonescimab Data at ELCC 2026
- Clinical Data Update: Summit Therapeutics will present updated data on ivonescimab at the 2026 European Lung Cancer Congress, covering intracranial anti-tumor activity from the global HARMONi Phase III study, which is expected to attract industry attention and enhance the company's reputation in cancer immunotherapy.
- Improved Intracranial Survival: In the HARMONi study, patients receiving ivonescimab plus chemotherapy showed an intracranial progression-free survival (PFS) of 10.1 months compared to 6.5 months for chemotherapy alone, indicating the potential advantage of this therapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients.
- Quality of Life Assessment: The second poster will showcase health-related quality of life data comparing ivonescimab with placebo plus chemotherapy, emphasizing the drug's potential to improve patient quality of life, which may enhance market recognition.
- Multiple Ongoing Trials: Ivonescimab is currently involved in over 15 Phase III clinical trials globally, covering various cancer types, indicating the company's extensive positioning in cancer treatment and future growth potential.
See More
Jefferies Downgrades Summit Therapeutics with Target Price Cut
- Rating Downgrade: Jefferies downgraded Summit Therapeutics from Buy to Hold, reflecting a cautious market outlook on the company's future performance amid uncertainties.
- Target Price Revision: The target price was significantly cut from $42 to $15, indicating a reassessment of the company's growth potential, which may impact investor confidence and lead to stock price volatility.
- Clinical Trial Progress: Summit completed screening for the squamous cohort in Q1 2026, with enrollment for the non-squamous cohort expected to finish in the second half of the year, potentially supporting future treatment options for the company.
- Financial Performance: The company reported an adjusted EPS of -$0.14 for Q4, exceeding the market consensus of -$0.01, demonstrating operational resilience despite a challenging overall market environment.
See More
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
- Regulatory Application Progress: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, survival data from Western countries has not shown statistical significance, potentially jeopardizing its marketing authorization.
- Market Valuation Changes: Currently, Summit's market cap stands at $12 billion, approximately 48% higher than Axsome and 17% higher than Madrigal, but if the FDA declines ivonescimab, the stock could face a drop of over 20%.
- Competitor Dynamics: Axsome Therapeutics and Madrigal Pharmaceuticals reported revenue growth of 65.5% and 432% in 2025, respectively, indicating strong market potential that could see them surpass Summit in the near future.
- Investor Risk Assessment: While Summit has long-term potential in oncology, its short-term outlook is uncertain, prompting investors to carefully evaluate risks, especially in light of possible negative clinical trial outcomes.
See More
Summit Therapeutics Faces FDA Approval Risk for Ivonescimab
- FDA Approval Crucial: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, the drug has not shown statistically significant overall survival in Western countries, and a rejection could lead to a significant drop in stock price.
- Intensifying Market Competition: Axsome Therapeutics and Madrigal Pharmaceuticals have market caps of $8.1 billion and $10.2 billion respectively, with both companies poised to potentially surpass Summit by 2026, highlighting the fierce competition in the biotech sector.
- Axsome's Growth Momentum: Axsome Therapeutics reported a 65.5% revenue increase in 2025, reaching $638.5 million, and is awaiting FDA approval for its Alzheimer's drug AXS-05, which could significantly expand its market reach.
- Madrigal's Sales Surge: Madrigal Pharmaceuticals achieved $958.4 million in sales from its Rezdiffra drug in 2025, a 432% increase from 2024, indicating strong growth potential in the metabolic dysfunction space, with expectations for continued excellent financial performance.
See More
U.S. Markets Increased on Wednesday; Summit Therapeutics Led the Way
- U.S. Stock Market Performance: U.S. stock indexes experienced gains on Wednesday, with the S&P 500 rising by 0.77%.
- Index Increases: The Dow Jones Industrial Average increased by 0.66%, while the Nasdaq Composite saw a rise of 0.54%.
See More
Citi Identifies Stocks with Upside Amid U.S.-Iran Conflict
- Market Turmoil Impact: The ongoing U.S.-Iran conflict has caused concern among investors, leading to a nearly 8% drop in the S&P 500 in March, marking its worst monthly performance since 2022.
- Citi Analyst Strategy: Citi analyst Richard Schlatter sought stocks that could sidestep recent volatility by overlaying crowding composites tracked by Citi, identifying stocks with positive catalysts that are not relatively crowded, aiming for a favorable reaction to fundamental tailwinds.
- Delta Air Lines Outlook: Delta Air Lines' stock has only dropped 3.8% this month, despite a nearly 9% decline in 2026, with Wall Street expecting a rebound; the average analyst price target from LSEG suggests a potential 25% gain over the next year.
- Summit Therapeutics Performance: Summit Therapeutics' stock has risen 2.4% since the war began, with a long crowding composite of just 18.1%, and analysts are generally bullish, as 13 out of 18 covering analysts rate it a buy or strong buy.
See More
Summit Presents Updated Ivonescimab Data at ELCC 2026
- Clinical Data Update: Summit Therapeutics will present updated data on ivonescimab at the 2026 European Lung Cancer Congress, covering intracranial anti-tumor activity from the global HARMONi Phase III study, which is expected to attract industry attention and enhance the company's reputation in cancer immunotherapy.
- Improved Intracranial Survival: In the HARMONi study, patients receiving ivonescimab plus chemotherapy showed an intracranial progression-free survival (PFS) of 10.1 months compared to 6.5 months for chemotherapy alone, indicating the potential advantage of this therapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients.
- Quality of Life Assessment: The second poster will showcase health-related quality of life data comparing ivonescimab with placebo plus chemotherapy, emphasizing the drug's potential to improve patient quality of life, which may enhance market recognition.
- Multiple Ongoing Trials: Ivonescimab is currently involved in over 15 Phase III clinical trials globally, covering various cancer types, indicating the company's extensive positioning in cancer treatment and future growth potential.
See More
Jefferies Downgrades Summit Therapeutics with Target Price Cut
- Rating Downgrade: Jefferies downgraded Summit Therapeutics from Buy to Hold, reflecting a cautious market outlook on the company's future performance amid uncertainties.
- Target Price Revision: The target price was significantly cut from $42 to $15, indicating a reassessment of the company's growth potential, which may impact investor confidence and lead to stock price volatility.
- Clinical Trial Progress: Summit completed screening for the squamous cohort in Q1 2026, with enrollment for the non-squamous cohort expected to finish in the second half of the year, potentially supporting future treatment options for the company.
- Financial Performance: The company reported an adjusted EPS of -$0.14 for Q4, exceeding the market consensus of -$0.01, demonstrating operational resilience despite a challenging overall market environment.
See More
Summit Therapeutics Faces FDA Review Risk for Ivonescimab
- Regulatory Application Progress: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, survival data from Western countries has not shown statistical significance, potentially jeopardizing its marketing authorization.
- Market Valuation Changes: Currently, Summit's market cap stands at $12 billion, approximately 48% higher than Axsome and 17% higher than Madrigal, but if the FDA declines ivonescimab, the stock could face a drop of over 20%.
- Competitor Dynamics: Axsome Therapeutics and Madrigal Pharmaceuticals reported revenue growth of 65.5% and 432% in 2025, respectively, indicating strong market potential that could see them surpass Summit in the near future.
- Investor Risk Assessment: While Summit has long-term potential in oncology, its short-term outlook is uncertain, prompting investors to carefully evaluate risks, especially in light of possible negative clinical trial outcomes.
See More
Summit Therapeutics Faces FDA Approval Risk for Ivonescimab
- FDA Approval Crucial: Summit Therapeutics has filed for FDA approval of ivonescimab, which is already approved in China; however, the drug has not shown statistically significant overall survival in Western countries, and a rejection could lead to a significant drop in stock price.
- Intensifying Market Competition: Axsome Therapeutics and Madrigal Pharmaceuticals have market caps of $8.1 billion and $10.2 billion respectively, with both companies poised to potentially surpass Summit by 2026, highlighting the fierce competition in the biotech sector.
- Axsome's Growth Momentum: Axsome Therapeutics reported a 65.5% revenue increase in 2025, reaching $638.5 million, and is awaiting FDA approval for its Alzheimer's drug AXS-05, which could significantly expand its market reach.
- Madrigal's Sales Surge: Madrigal Pharmaceuticals achieved $958.4 million in sales from its Rezdiffra drug in 2025, a 432% increase from 2024, indicating strong growth potential in the metabolic dysfunction space, with expectations for continued excellent financial performance.
See More
U.S. Markets Increased on Wednesday; Summit Therapeutics Led the Way
- U.S. Stock Market Performance: U.S. stock indexes experienced gains on Wednesday, with the S&P 500 rising by 0.77%.
- Index Increases: The Dow Jones Industrial Average increased by 0.66%, while the Nasdaq Composite saw a rise of 0.54%.
See More
